These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 20220779)

  • 41. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
    Muto T; Walker CS; Agarwal P; Vick E; Sampson A; Choi K; Niederkorn M; Ishikawa C; Hueneman K; Varney M; Starczynowski DT
    Haematologica; 2023 Oct; 108(10):2715-2729. PubMed ID: 37102608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Detection of common chromosome abnormalities in myelodysplastic syndrome with a panel fluorescence in situ hybridization].
    Shen Y; Xue Y; Li J; Pan J; Wu Y; Chen S
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):160-3. PubMed ID: 12673589
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
    Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
    Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conventional and molecular cytogenetic findings of myelodysplastic syndrome patients.
    Yilmaz Z; Sahin FI; Kizilkilic E; Karakus S; Boga C; Ozdogu H
    Clin Exp Med; 2005 Jul; 5(2):55-9. PubMed ID: 16096854
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells.
    Vidovic K; Svensson E; Nilsson B; Thuresson B; Olofsson T; Lennartsson A; Gullberg U
    Leukemia; 2010 May; 24(5):992-1000. PubMed ID: 20237505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differentially expressed genes in adult familial myelodysplastic syndromes.
    Pradhan A; Mijovic A; Mills K; Cumber P; Westwood N; Mufti GJ; Rassool FV
    Leukemia; 2004 Mar; 18(3):449-59. PubMed ID: 14737073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS.
    Lane SW; Sykes SM; Al-Shahrour F; Shterental S; Paktinat M; Lo Celso C; Jesneck JL; Ebert BL; Williams DA; Gilliland DG
    Blood; 2010 Apr; 115(17):3489-97. PubMed ID: 20197553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes.
    Zatkova A; Merk S; Wendehack M; Bilban M; Muzik EM; Muradyan A; Haferlach C; Haferlach T; Wimmer K; Fonatsch C; Ullmann R
    Genes Chromosomes Cancer; 2009 Jun; 48(6):510-20. PubMed ID: 19306356
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.
    Keerthivasan G; Mei Y; Zhao B; Zhang L; Harris CE; Gao J; Basiorka AA; Schipma MJ; McElherne J; Yang J; Verma AK; Pellagatti A; Boultwood J; List AF; Williams DA; Ji P
    Blood; 2014 Jul; 124(5):780-90. PubMed ID: 24891322
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan.
    Tasaka T; Tohyama K; Kishimoto M; Ohyashiki K; Mitani K; Hotta T; Kanamaru A; Okamoto S; Karasawa M; Kimura A; Tomonaga M; Uchiyama T; Ozawa K;
    Leukemia; 2008 Oct; 22(10):1874-81. PubMed ID: 18668133
    [TBL] [Abstract][Full Text] [Related]  

  • 51. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
    Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
    Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome.
    Mallo M; Luño E; Sanzo C; Cervera J; Haase D; Schanz J; García-Manero G; del Cañizo C; Sanz GF; Solé F
    Leuk Res; 2011 Jun; 35(6):834-6. PubMed ID: 21269692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network.
    Fang J; Barker B; Bolanos L; Liu X; Jerez A; Makishima H; Christie S; Chen X; Rao DS; Grimes HL; Komurov K; Weirauch MT; Cancelas JA; Maciejewski JP; Starczynowski DT
    Cell Rep; 2014 Sep; 8(5):1328-38. PubMed ID: 25199827
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Muench DE; Ferchen K; Velu CS; Pradhan K; Chetal K; Chen X; Weirauch MT; Colmenares C; Verma A; Salomonis N; Grimes HL
    Blood; 2018 Nov; 132(21):e24-e34. PubMed ID: 30249787
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.
    Slape CI; Saw J; Jowett JB; Aplan PD; Strasser A; Jane SM; Curtis DJ
    Blood; 2012 Sep; 120(12):2475-83. PubMed ID: 22855610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential expression of microRNAs in CD34+ cells of 5q- syndrome.
    Votavova H; Grmanova M; Dostalova Merkerova M; Belickova M; Vasikova A; Neuwirtova R; Cermak J
    J Hematol Oncol; 2011 Jan; 4():1. PubMed ID: 21211043
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Knockdown of HSPA9 induces TP53-dependent apoptosis in human hematopoietic progenitor cells.
    Liu T; Krysiak K; Shirai CL; Kim S; Shao J; Ndonwi M; Walter MJ
    PLoS One; 2017; 12(2):e0170470. PubMed ID: 28178280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells.
    Ruiz-Gutierrez M; Bölükbaşı ÖV; Alexe G; Kotini AG; Ballotti K; Joyce CE; Russell DW; Stegmaier K; Myers K; Novina CD; Papapetrou EP; Shimamura A
    JCI Insight; 2019 Apr; 5(12):. PubMed ID: 31039138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcriptome analysis of CD34+ cells from myelodysplastic syndrome patients.
    Ou R; Huang J; Shen H; Liu Z; Zhu Y; Zhong Q; Zheng L; Yao M; She Y; Zhou S; Chen R; Li C; Zhang Q; Liu S
    Leuk Res; 2017 Nov; 62():40-50. PubMed ID: 28982058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways.
    Guerenne L; Beurlet S; Said M; Gorombei P; Le Pogam C; Guidez F; de la Grange P; Omidvar N; Vanneaux V; Mills K; Mufti GJ; Sarda-Mantel L; Noguera ME; Pla M; Fenaux P; Padua RA; Chomienne C; Krief P
    J Hematol Oncol; 2016 Jan; 9():5. PubMed ID: 26817437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.